Our Mission: Making Irish Medical Innovation Accessible to Chinese Patients
Founded by Mr. Feng Bo in Lecheng, a wholly foreign-owned enterprise leveraging 25 years of experience in Ireland. We deeply understand Irish medtech needs (commercialization, regulatory certainty, market expansion) and are fully integrated into China’s policy and business ecosystem.
oExclusive Representative: Sole authorized partner of Lecheng in Ireland
oMarket Potential: China’s healthcare market exceeds RMB X trillion
oTime Savings: Lecheng pathway reduces approval to months
We go beyond brokerage. We directly invest to acquire exclusive distribution rights for Irish innovative drugs/devices in China, sell through Lecheng’s medical tourism ecosystem, and represent companies in applying for nationwide NMPA approval.
Buyout distribution refers to obtaining the exclusive distribution rights for innovative drugs or medical devices from Ireland in China through direct investment. Simply put, enterprises are not just acting as intermediaries; instead, they gain exclusive sales rights for these innovative medical products in the Chinese market through capital investment. This ensures their unique advantage in market competition and lays the foundation for subsequent commercialization.
Lecheng fast-track commercialization relies on the special policies and ecosystem of the Boao Lecheng International Medical Tourism Pilot Zone. On one hand, by leveraging the medical tourism model, the acquired innovative drugs/devices are launched in 31 institutions in Lecheng, providing high-end diagnosis, treatment, and rehabilitation services. On the other hand, using the Real-World Data (RWD) accumulated in Lecheng, we apply for nationwide approval from the National Medical Products Administration (NMPA) on behalf of partners. This enables a rapid commercialization path from preliminary application in Lecheng to nationwide market promotion, saving 80% of clinical trial costs and allowing entry into the market 3-4 years earlier.
Boao Lecheng: Your China Market Accelerator
China’s first and only pilot zone for urgent clinical import of unapproved drugs/devices (State Council approved), featuring zero tariffs, RWD pilot, and “Four Special Permissions”.
Exclusive Access: We are your only authorized entry to Lecheng
Ultra-Fast Approval: Average 1.6 days for special access
Medical Tourism Ecosystem: 31 institutions + “Medical + Tourism” model drives rapid monetization
View Details
Exclusive authorization from Lecheng
Approval cycle of several months
Save 80% of clinical costs
Enter the market 3-4 years in advance
Cross cultural resource integration
